虽然2000年中旬安进在贫血和癌症领域有两种年销售额超过10亿美元的畅销药品,但往前看时,发现公司未来的增长动力干涸了。2001年,为促进研发,我将免疫学专家佩尔穆特招至麾下。佩尔穆特发现安进的问题并不在于缺少新点子,而在于用劲不专。正因为如此,安进中止了几乎不可能迅速成功的早期研究项目, Although Amgen had two best-selling drugs with annual sales of more than $ 1 billion in the area of ​​anemia and cancer in mid-2000, it found that the company’s future growth momentum dried up. In 2001, to promote research and development, I enlisted the immunologist Permut. Permut found that the problem with Amgen was not the lack of new ideas, but rather the lack of expertise. It is for this reason that Amgen discontinued early research projects that were almost impossible to succeed quickly,